Cancers, Vol. 12, Pages 1900: Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial)

In conclusion, combination of sorafenib + pravastatin was safe and well-tolerated, prolonging the TTP of patients with aHCC but not improving the OS compared to sorafenib + placebo. The absence of PVT and VI and the development of DE are positive prognostic factors of sorafenib response.

Source: Cancers - July 13, 2020 Category: Cancer & Oncology Authors: Ria ño Mart ín Varela Serrano N úñez M ínguez Rodrigues Perugorria Banales Arenas Tags: Article Source Type: research